β-amyloid fibrillation and/or hyperhomocysteinemia modify striatal patterns of hyaluronic acid and dermatan sulfate: Possible role in the pathogenesis of Alzheimer's disease

Current Alzheimer Research

Volumn 7, Issue 2, 2010, Pages 150-157

  Genedani, S ^a   Agnati, L F ^a   Leo, G ^a   Buzzega, D ^a   Maccari, F ^a   Carone, C ^a   Andreoli, N ^a   Filaferro, M ^a   Volpi, N ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

amyloid; Alzheimer's disease; Chondroitin sulphate; Dermatan sulphate; Glycosaminoglycans; Homocysteine; Hyaluronic acid

Indexed keywords

BETA SECRETASE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HYALURONIC ACID;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CORPUS STRIATUM; EXTRACELLULAR MATRIX; HYPERHOMOCYSTEINEMIA; MALE; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CORPUS STRIATUM; DERMATAN SULFATE; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCANS; HYALURONIC ACID; HYPERHOMOCYSTEINEMIA; MALE; RATS; RATS, SPRAGUE-DAWLEY; SENILE PLAQUES; SULFATES;

EID: 77949724546     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790691074     Document Type: Article

References (47)

1. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin 25: 577-609 (2007).
2. Jellinger KA. Alzheimer 100 - highlights in the history of Alzheimer research. J Neural Transm 113: 1603-23 (2006).
3. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 368: 387-403 (2006).
4. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of β-amyloid 40 and 42. Neurobiol Dis 20: 74-81 (2005).
5. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl J Med 346: 476-83 (2002).
6. Genedani S, Rasio G, Cortelli P, Antonelli F, Guidolin D, Galantucci M, et al. Studies on homocysteine and dehydroepiandrsterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. Neurotox Res 6: 327-32 (2004).
7. Leo G, Genedani S, Filaferro M, Carone C, Andreoli N, Astancolle S, et al. Hyper-homocysteinemia alters amyloid peptide-clusterin interactions and neuroglial network morphology and function in the caudate after intrastriatal injection of amyloid peptides. Curr Alzheimer Dis 4: 305-13 (2007).
8. Agnati LF, Genedani S, Leo G, Forni A, Woods AS, Filaferro M, et al. Aβ peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease. J Neural Transm 114: 21-31 (2007).
9. Sipe J. Amyloidosis. Annu Rev Biochem 61: 947-75 (1992).
10. Fraser RE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 59: 1531-1540 (1992).
11. Gupta-Bansal R, Frederickson RCA, Brunden KR. Proteoglycanmediated inhibition of Aβ proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 270: 18666-71 (1995).
12. Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RCA, Younkin SG, Brunden KR. Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiol Aging 16: 737-45 (1995).
13. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's discase, accelerates Aβ fibril formation, and maintains Aβ fibril stability. J Neurochem 69: 2452-65 (1997).
14. Snow AD, Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab Invest L53: 37-44 (1985).
15. Castillo GM, Lukito W, Wight TN, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J Neurochem 72: 1681-87 (1999).
16. Snow AD, Mar H, Nochlin D, Rimata K, Rato M, Suzuki S, et al. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133: 456-63 (1988).
17. Snow AD, Nochlin D, Sekiguchi R, Carlson SS. Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Exp Neurol 138: 305-17 (1996).
18. Snow AD, Mar H, Nochlin D, Kresse H, Wight TN. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J Histochem Cytochem 40: 105-13 (1992).
19. Dewitt DA, Silver J, Canning DR, Perry G. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 121: 149-52 (1993).
20. Sen U, Herrmann M, Herrmann W, Tyagi SC. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling. Clin Chem Lab Med 45: 1771-6 (2007).
21. Liu X, Luo F, Li J, Wu W, Li L, Chen H. Homocysteine induces connective tissue growth factor expression in vascular smooth muscle cells. J Thromb Haemost 6: 184-92 (2008).
22. Ma Q, Cornelli U, Hanin I, Jeske WP, Linhardt RJ, Walenga JM, et al. Heparin oligosaccharides as potential therapeutic agents in senile dementia. Curr Pharm Des 13: 1607-16 (2007).
23. Cesaretti M, Luppi E, Maccari F, Volpi N. A 96-well assay for uronic acid carbazole reaction. Carbohydr Polym 54: 59-61 (2003).
24. Paxinos G, Watson CR, Emson PC. AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 3: 129-49 (1980).
25. Calabro A, Benavides M, Tammi M, Hascall VC, Midura RJ. Microanalysis of enzyme digests of hyaluronan and chondroitin/ dermatan sulfate by fluorophore-assisted carbohydrate electrophoresis (FACE). Glycobiology 10: 273-81 (2000).
26. Volpi N, Maccari F. Composition of urinary glycosaminoglycans in a patient with pseudoxanthoma elasticum and familial Mediterranean fever. Clin Chim Acta 359: 207-9 (2005).
27. Volpi N, Maccari F. Glycosaminoglycans composition of the large freshwater mollusc bivalve Anodonta anodonta. Biomacro-molecules 6: 3174-80 (2005).
28. Volpi N, Maccari F. Electrophoretic approaches to the analysis of complex polysaccharides. J Chrom B 834: 11-13 (2006).
29. Volpi N, Maccari F, Titze J. Simultaneous detection of submicrogram quantities of hyaluronic acid and dermatan sulfate on agarose-gel by sequential staining with toluidine blue and Stains-All. J Chrom B 820: 131-5 (2005).
30. Volpi N, Maccari F. Detection of submicrogram quantities of glycosaminoglycans on agarose-gels by sequential staining with toluidine blue and Stains-All. Electrophoresis 23: 4060-66 (2002).
31. Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 15: 3932-3942 (1976).
32. Volpi N. Advances in chondroitin sulfate analysis: application in physiological and pathological states of connective tissue and during pharmacological treatment of osteoarthritis. Curr Pharm Design 12: 639-658 (2006).
33. Oohira A, Matsui F, Matsuda M, Shoji R. Developmental change in the glycosaminoglycan composition of the rat brain. J Neurochem 47: 588-593 (1988).
34. Jenkins HG, Bachelard HS. Developmental and age-related changes in rat brain glycosaminoglycans. J Neurochem 51: 1634-1640 (1988).
35. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2: 482-492 (2003).
36. Lindahl B, Eriksson L, Spillmann D, Caterson B, Lindahl U. Selective loss of cerebral keratan sulfate in Alzheimer's disease. J Biol Chem 271: 16991-16994 (1996).
37. Small DH, Williamson T, Reed G, Clarris H, Beyreuther K, Masters CL, et al. The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Ann NY Acad Sci 777: 316-21 (1996).
38. McLaurin J, Fraser PE. Effect of amino-acid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions. Eur J Biochem 267: 6353-61 (2000).
39. Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells. Neurosci Lett 184: 113-6 (1995).
40. Woods AG, Cribbs DH, Whittemore ER, Cotman CW. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate β-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res 697: 53-62 (1995).
41. Díaz-Nido J, Wandosell F, Avila J. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23: 1323-32 (2002).
42. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 49: 31-62 (1998).
43. Miyao M, Morita H, Hosoi T, Kurihara H, Inoue S, Hoshino S, et al. Methylenetetrahydrofolate reductase polymorphism and bone mineral density in postmenopausal Japanese women. J Bone Mineral Res 13: S373, W304 (1998).
44. Moshal KS, Singh M, Sen U, Rosenberger DS, Henderson B, Tyagi N, et al. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 291: H2825-35 (2006).
45. Kumar M, Tyagi N, Moshal KS, Sen U, Pushpakumar SB, Vacek T, et al. GABA(A) receptor agonist mitigates homocysteine-induced cerebrovascular remodeling in knockout mice. Brain Res 1221: 147-53 (2008).
46. Sen U, Herrmann M, Herrmann W, Tyagi SC. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling. Clin Chem Lab Med 45: 1771-6 (2007).
47. Lominadze D, Roberts AM, Tyagi N, Moshal KS, Tyagi SC. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol 290: H1206-H13 (2006).